The absence of any hantavirus vaccine candidate in Phase 3 trials or beyond drives the 94.5% market-implied probability against FDA full approval by December 31, 2026. Current efforts center on preclinical mRNA and DNA platforms targeting orthohantavirus Gn-Gc glycoproteins, with recent 2026 structural insights from NIH-funded work enabling neutralizing antibody production in animal models; however, no candidates have advanced to large-scale human efficacy testing. Low disease incidence, rodent-borne transmission patterns, and typical multi-year regulatory timelines limit feasibility, even after a May 2026 cruise-ship Andes virus cluster prompted modest surveillance funding. An unexpected emergency use authorization could theoretically shift outcomes, though such precedents remain absent for this pathogen.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गयाHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% संभावना
$129,605 वॉल्यूम
$129,605 वॉल्यूम
31 दिस, 2026
6% संभावना
$129,605 वॉल्यूम
$129,605 वॉल्यूम
31 दिस, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The absence of any hantavirus vaccine candidate in Phase 3 trials or beyond drives the 94.5% market-implied probability against FDA full approval by December 31, 2026. Current efforts center on preclinical mRNA and DNA platforms targeting orthohantavirus Gn-Gc glycoproteins, with recent 2026 structural insights from NIH-funded work enabling neutralizing antibody production in animal models; however, no candidates have advanced to large-scale human efficacy testing. Low disease incidence, rodent-borne transmission patterns, and typical multi-year regulatory timelines limit feasibility, even after a May 2026 cruise-ship Andes virus cluster prompted modest surveillance funding. An unexpected emergency use authorization could theoretically shift outcomes, though such precedents remain absent for this pathogen.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
बाज़ार खुला: May 4, 2026, 10:39 AM ET
वॉल्यूम
$129,605समाप्ति तिथि
31 दिस, 2026बाज़ार खुला
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.The absence of any hantavirus vaccine candidate in Phase 3 trials or beyond drives the 94.5% market-implied probability against FDA full approval by December 31, 2026. Current efforts center on preclinical mRNA and DNA platforms targeting orthohantavirus Gn-Gc glycoproteins, with recent 2026 structural insights from NIH-funded work enabling neutralizing antibody production in animal models; however, no candidates have advanced to large-scale human efficacy testing. Low disease incidence, rodent-borne transmission patterns, and typical multi-year regulatory timelines limit feasibility, even after a May 2026 cruise-ship Andes virus cluster prompted modest surveillance funding. An unexpected emergency use authorization could theoretically shift outcomes, though such precedents remain absent for this pathogen.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
वॉल्यूम
$129,605समाप्ति तिथि
31 दिस, 2026बाज़ार खुला
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...The absence of any hantavirus vaccine candidate in Phase 3 trials or beyond drives the 94.5% market-implied probability against FDA full approval by December 31, 2026. Current efforts center on preclinical mRNA and DNA platforms targeting orthohantavirus Gn-Gc glycoproteins, with recent 2026 structural insights from NIH-funded work enabling neutralizing antibody production in animal models; however, no candidates have advanced to large-scale human efficacy testing. Low disease incidence, rodent-borne transmission patterns, and typical multi-year regulatory timelines limit feasibility, even after a May 2026 cruise-ship Andes virus cluster prompted modest surveillance funding. An unexpected emergency use authorization could theoretically shift outcomes, though such precedents remain absent for this pathogen.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न